Safety, tolerability, and pharmacokinetics of the novel RdRp inhibitor SHEN26 against SARS-CoV-2: a randomized, placebo-controlled, double-blind Phase I study in healthy subjects.
Cheng SunHao LiuZiwei OuyangJie DingQin ZhangHongjie MaDandan XuQian ZhangRenpeng ZhouMingming YangWei HuPublished in: Expert opinion on investigational drugs (2024)
The trial is registered in ClinicalTrials.gov (CT. gov identifier: NCT05504746).
Keyphrases
- placebo controlled
- double blind
- phase iii
- phase ii
- sars cov
- study protocol
- clinical trial
- open label
- phase ii study
- computed tomography
- randomized controlled trial
- contrast enhanced
- magnetic resonance imaging
- respiratory syndrome coronavirus
- radiation therapy
- image quality
- magnetic resonance
- positron emission tomography
- dual energy
- coronavirus disease